89bio, Inc. Files 8-K: Agreements, Acquisitions, Delisting Concerns
| Field | Detail |
|---|---|
| Company | 89bio, Inc. |
| Form Type | 8-K |
| Filed Date | Oct 30, 2025 |
| Risk Level | high |
| Pages | 12 |
| Reading Time | 15 min |
| Key Dollar Amounts | $0.001, $14.50, $6.00, $20.50 b, $20.50 |
| Sentiment | mixed |
Sentiment: mixed
Topics: agreement-termination, acquisition, delisting-notice, corporate-governance
TL;DR
89bio's 8-K is a mess: terminated deals, acquisition issues, and possible delisting. Big changes ahead.
AI Summary
On October 30, 2025, 89bio, Inc. filed an 8-K report detailing several significant events. These include the termination of a material definitive agreement, completion of an acquisition or disposition of assets, and notice of potential delisting or failure to meet listing standards. The company also reported material modifications to security holder rights, changes in control, and updates regarding directors and officers, including compensatory arrangements. Additionally, amendments to its articles of incorporation or bylaws and changes to its fiscal year were noted, along with the filing of financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions and potential financial distress for 89bio, Inc., which could impact its stock price and investor confidence.
Risk Assessment
Risk Level: high — The filing mentions termination of material agreements, potential delisting, and changes in control, all of which signal significant operational and financial instability.
Key Players & Entities
- 89bio, Inc. (company) — Registrant
- October 30, 2025 (date) — Date of earliest event reported
FAQ
What specific material definitive agreement was terminated by 89bio, Inc.?
The filing does not specify the details of the terminated material definitive agreement.
What was acquired or disposed of by 89bio, Inc.?
The filing indicates the completion of an acquisition or disposition of assets but does not provide specific details about the assets involved.
What are the reasons for the notice of delisting or failure to satisfy a continued listing rule for 89bio, Inc.?
The filing does not specify the exact reasons for the notice of delisting or failure to satisfy listing rules.
Were there any changes in the control of 89bio, Inc. reported in this filing?
Yes, the filing indicates that there were changes in the control of the registrant.
What changes were made to 89bio, Inc.'s articles of incorporation or bylaws?
The filing mentions amendments to the articles of incorporation or bylaws but does not detail the specific changes made.
Filing Stats: 3,655 words · 15 min read · ~12 pages · Grade level 12.9 · Accepted 2025-10-30 09:03:20
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ETNB The Nasdaq Global Ma
- $14.50 — .001 per share, of the Company, for (i) $14.50 per Share, in cash, without interest (t
- $6.00 — ayments of up to an aggregate amount of $6.00 per Share in cash, without interest les
- $20.50 b — rcise price per Share that is less than $20.50 became entitled to receive from the Survi
- $20.50 — price that is equal to or greater than $20.50 was cancelled as of immediately prior t
- $75,000 — payment of a transaction bonus equal to $75,000, $300,000 and $250,000, respectively, i
- $300,000 — f a transaction bonus equal to $75,000, $300,000 and $250,000, respectively, in connecti
- $250,000 — on bonus equal to $75,000, $300,000 and $250,000, respectively, in connection with the M
- $100,000 — schuler, whose supplemental retainer is $100,000 (each, a " Cash Retainer "). The Compan
Filing Documents
- d48446d8k.htm (8-K) — 59KB
- d48446dex31.htm (EX-3.1) — 5KB
- d48446dex32.htm (EX-3.2) — 86KB
- d48446dex101.htm (EX-10.1) — 14KB
- g48446dsp001.jpg (GRAPHIC) — 5KB
- g48446dsp002.jpg (GRAPHIC) — 3KB
- 0001193125-25-257616.txt ( ) — 328KB
- etnb-20251030.xsd (EX-101.SCH) — 3KB
- etnb-20251030_lab.xml (EX-101.LAB) — 18KB
- etnb-20251030_pre.xml (EX-101.PRE) — 11KB
- d48446d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit Description 2.1* Agreement and Plan of Merger, dated as of September 17, 2025, by and among 89bio, Inc., Roche Holdings, Inc. and Bluefin Merger Subsidiary, Inc. (incorporated by reference to Exhibit 2.1 to 89bio, Inc.'s Current Report on Form 8-K (No. 001-39122), filed with the SEC on September 18, 2025). 3.1 Third Amended and Restated Certificate of Incorporation of 89bio, Inc. 3.2 Fourth Amended and Restated Bylaws of 89bio, Inc. 10.1 Form of Transaction Bonus Letter Agreement. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document) * Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 89bio, Inc. Date: October 30, 2025 By: /s/ Rohan Palekar Name: Rohan Palekar Title: Chief Executive Officer